Introduction: Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination therapy in non-responders to PDE5i. We will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.
Methods And Analysis: This overview was designed in accordance with the PRIO-harms and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and its protocol was registered at PROSPERO. We will systematically search PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. We will include systematic reviews or meta-analyses: (1) comparing the efficacy and safety of any dose of PDE5i with each other, with placebo or with other effective treatments for the management of erectile function; (2) exploring the use of any PDE5i alone or in combination with other treatment modalities in the general male population or in specific subgroups and (3) conducted with systematic procedures. Our overview will employ the AMSTAR 2 tool to evaluate the quality of the included studies and the Grading of Recommendations Assessment, Development and Evaluation approach to assess the strength of evidence for all outcomes. We will construct forest plots of risk estimates with the corresponding CI for all outcomes.
Ethics And Dissemination: In this overview, we will undertake an extensive literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i versus another or versus placebo and provide recommendations for clinicians and policy-makers. No ethical approval is required.
Prospero Registration Number: CRD42020216754.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386228 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2020-047396 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Keck School of Medicine of USC, Los Angeles, CA, USA.
Background: Research on biomarkers for Alzheimer's pathology has progressed rapidly. We summarize the evidence and make recommendations about biomarkers for future clinical use.
Method: Our interdisciplinary, international, multicultural group of experts in the Lancet Commission on dementia adopted a triangulation framework, prioritizing systematic reviews and meta-analyses and agreed on the best evidence for recommendations.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Faculty of Medicine, University of Oslo, Oslo, Norway.
Background: While symptomatic treatment for Alzheimer's disease has been available for three decades disease modifying treatment does not exist. New drug treatments, known as immunotherapies, which remove amyloid from the brain offer hope, but the clinical significance remains uncertain.
Method: Systematic reviews of the literature, expert consensus, and information from clinical environments.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The 2020 Lancet Commission on dementia prevention, intervention and care estimated that up to 40% of dementia cases could be prevented by tackling 12 potentially modifiable risk factors, namely less education, hearing loss, hypertension, physical inactivity, diabetes, social isolation, excessive alcohol consumption, air pollution, smoking, obesity, traumatic brain injury, depression. As more evidence on risk factors emerges, the Lancet standing commission on dementia met to update evidence on established dementia risk factors and to consider the evidence for other risk factors.
Method: We used a lifecourse approach to understand how to reduce risk or prevent dementia, as many risks operate at different timepoints in the lifespan.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of Georgia, College of Pharmacy, Athens, GA, USA.
Background: Reducing chronic inflammation has been linked to anti-inflammatory foods and may be implicated in treating Alzheimer's disease (AD). Plants produce antioxidants, such as phytochemicals, that appear to reduce the incidence of chronic inflammatory diseases. Phytochemicals may include active substances like polyphenols.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of Georgia, College of Pharmacy, Athens, GA, USA.
Background: Lipids are key modulators in the pathogenesis of Alzheimer's disease (AD). Dysregulation of lipid homeostasis may disrupt the blood brain barrier, alter myelination, disturb cellular signaling and cause abnormal processing of the amyloid precursor protein. The purpose of this scoping review was to evaluate fatty acid supplementation in patients with AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!